SCHEMBL10270248

SCHEMBL10270248

Cc1c(Cl)cccc1C(CNS(C)(=O)=O)NC(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AVPR2 P30518 2/20 0.40
▸ AVPR1A P37288 2/20 0.40
▸ LMNA P02545 5/20 0.38
▸ HPGD P15428 5/20 0.38
▸ HTT P42858 5/20 0.38
▸ NPSR1 Q6W5P4 5/20 0.38
▸ HSD17B10 Q99714 3/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ MITF O75030 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ ALDH1A1 P00352 4/20 0.36
▸ PKM P14618 3/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ JAK2 O60674 3/20 0.36
▸ XBP1 P17861 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ ALOX15 P16050 2/20 0.36
▸ TSHR P16473 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CA12 O43570 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10216786 0.90 AVPR2 (0.46) AVPR2AVPR1ALMNAHPGDHTT
SCHEMBL10217111 0.90 CA12 (0.41) AVPR2AVPR1ALMNAHPGDHTT
SCHEMBL10270827 0.84 LMNA (0.44) LMNAHPGDHTTNPSR1HSD17B10
SCHEMBL10216785 0.80 AVPR2 (0.45) AVPR2AVPR1ALMNAHPGDHTT
SCHEMBL10217106 0.80 SYK (0.40) AVPR2AVPR1ALMNAHPGDHTT
SCHEMBL10216773 0.79 AVPR2 (0.46) AVPR2AVPR1ALMNAHPGDHTT
SCHEMBL387950 0.78 PPARA (0.42) LMNAMAPTALDH1A1TSHR
SCHEMBL10217116 0.75 HPGD (0.41) LMNAHPGDHTTNPSR1HSD17B10
SCHEMBL3446491 0.75 CTSA (0.40) LMNAALDH1A1KMT2AMEN1
SCHEMBL3447391 0.74 CTSA (0.44) LMNAHTTNPSR1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202895-B2 Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-06-19 — — US disclosed
US-20100261771-A1 SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261771-A1 SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF AADAC, NAT1, TNNT2 AVPR2 2370/4885AVPR1A 3230/4885LMNA 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback